Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy （chemotherapy or abiraterone）？—

摘要 Palliativeradiotherapy(pRT)isprimarilyemployedforpalliationofbonepaininpatientswithcastrate-resistantprostatecancer(CRPC).However,evidencethatpRTinfluencesprostate-specificantigenresponseinpatientswithCRPConsystemictherapyislacking.WedescribethreecasesofCRPCprogressingaftertreatmentwithdocetaxel(n=2)andabiraterone(n=1),whorespondedunusuallyafterpRTforbonepainwiththedevelopmentofasignificantbiochemicalresponseandrestorationofresponsetosystemictherapy.ThepossibilityofpRTinfluencingmetastaticdiseaseinCRPChasnotbeenpreviouslyreported,andraisesthepossibilityofradiation-inducedmodulationofanti-tumorimmuneresponsemechanismsthatmayplayaroleintherestorationofresponsetosystemictreatment.

1Oliver Sartor;Silke Gillessen. Treatment sequencing in metastatic castrate-resistant prostate cancer.泌尿科学,2014-03.
2Jeremv YC Teoh;Steffi KK Yuen;James HL Tsu;Charles KW Wong;Brian SH Ho;Ada TL Ng;Wai-Kit Ma;Kwan-Lun Ho;Ming-Kwong Yiu. The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men.泌尿科学,2017-01.
3Atsushi Mizokami;Kouji Izumi;Hiroyuki Konaka;Yasuhide Kitagawa;Yoshifumi Kadono;Kazutaka Narimoto;Takahiro Nohara;Amit K Bahl;Mikio Namiki. Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer： implications for clinical practice.泌尿科学,2017-02.
4Paul J Toren Martin E Gleave. Evolving landscape and novel treatments in, metastatic castrate-resistant prostate cancer.泌尿科学,2013-03.
5Rui Chen;Li-Qun Zhou;Xiao-Bing Cai;Li-Ping Xie;Yi-Ran Huang;Da-Lin He;Xu Gao;Chuan-Liang Xu;Qiang Ding;Qiang wei;Chang-Jun Yin;Shan-Cheng Ren;Fu-Bo Wang;Ye Tian;Zhong-Quan Sun;Qiang Fu;Lu-Lin Ma;Jun-Hua Zheng;Zhang-Qun Ye;Ding-Wei Ye;Dan-Feng Xu;Jian-Quan Hou;Ke-Xin Xu;Jian-Lin Yuan;Xin Gao;Chun-Xiao Liu;Tie-Jun Pan;Ying-Hao Sun. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml^-1.泌尿科学,2015-06.
6Yun-Jie Yang;Guo-Wen Lin;Gao-Xiang Li;Bo Dai;Ding-Wei Ye;Jun-Long Wu;Hu-Yang Xie;Yao Zhu. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer.泌尿科学,2018-02.
7Rita Nader;Joelle El Amm;Jeanny B Aragon-Ching. Role of chemotherapy in prostate cancer.泌尿科学,2018-03.
8Costanza Chiumento Alba Fiorentino Mariella Cozzolino Rocchina Caivano Stefania Clemente Piernicola Pedicini Vincenzo Fusco. Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy.肿瘤,2013-03.
9Yuri Stanevsky;Alexander Tsivian;Matvey Tsivian. Castration-resistant prostate cancer： a strategy to enhance response to androgen deprivation.泌尿科学,2013-06.
10Seok-Ho Kang Jin-Wook Kim Jae-Hyun Bae Hong-Seok Park Du-Geon Moon Duck-Ki Yoon Jun Cheon Je-Jong Kim. Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy： quality of life in high-risk prostate cancer patients.泌尿科学,2006-05.

Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy （chemotherapy or abiraterone）？——a report of three cases

来源期刊

相关推荐

同分类资源更多

相关关键词

Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy （chemotherapy or abiraterone）？——a report of three cases

来源期刊

相关推荐

同分类资源 更多

相关关键词

同分类资源更多